Search Results - "Journal of hepatology"

A multisociety Delphi consensus statement on new fatty liver disease nomenclature by Rinella, Mary E, Lazarus, Jeffrey V, Ratziu, Vlad, Francque, Sven M, Sanyal, Arun J, Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F, Anstee, Quentin M, Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher D, Castro Narro, Graciela E, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna R, Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D, Harrison, Stephen A, Kim, Seung Up, Koot, Bart G, Korenjak, Marko, Kowdley, Kris V, Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R, Powell, Elisabeth E, Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C, Spearman, C Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B, Wong, Vincent Wai-Sun, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, Newsome, Philip N

“…The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This…”
Get full text

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update by Reig, Maria, Forner, Alejandro, Rimola, Jordi, Ferrer-Fàbrega, Joana, Burrel, Marta, Garcia-Criado, Ángeles, Kelley, Robin K., Galle, Peter R., Mazzaferro, Vincenzo, Salem, Riad, Sangro, Bruno, Singal, Amit G., Vogel, Arndt, Fuster, Josep, Ayuso, Carmen, Bruix, Jordi

“…There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer…”
Get full text

Global burden of primary liver cancer in 2020 and predictions to 2040 by Rumgay, Harriet, Arnold, Melina, Ferlay, Jacques, Lesi, Olufunmilayo, Cabasag, Citadel J., Vignat, Jérôme, Laversanne, Mathieu, McGlynn, Katherine A., Soerjomataram, Isabelle

“…The burden of liver cancer varies across the world. Herein, we present updated estimates of the current global burden of liver cancer (incidence and mortality)…”
Get full text

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma by Cheng, Ann-Lii, Qin, Shukui, Ikeda, Masafumi, Galle, Peter R., Ducreux, Michel, Kim, Tae-You, Lim, Ho Yeong, Kudo, Masatoshi, Breder, Valeriy, Merle, Philippe, Kaseb, Ahmed O., Li, Daneng, Verret, Wendy, Ma, Ning, Nicholas, Alan, Wang, Yifan, Li, Lindong, Zhu, Andrew X., Finn, Richard S.

“…IMbrave150 demonstrated that atezolizumab plus bevacizumab led to significantly improved overall survival (OS) and progression-free survival (PFS) compared…”
Get full text

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement by Eslam, Mohammed, Newsome, Philip N., Sarin, Shiv K., Anstee, Quentin M., Targher, Giovanni, Romero-Gomez, Manuel, Zelber-Sagi, Shira, Wai-Sun Wong, Vincent, Dufour, Jean-François, Schattenberg, Jörn M., Kawaguchi, Takumi, Arrese, Marco, Valenti, Luca, Shiha, Gamal, Tiribelli, Claudio, Yki-Järvinen, Hannele, Fan, Jian-Gao, Grønbæk, Henning, Yilmaz, Yusuf, Cortez-Pinto, Helena, Oliveira, Claudia P., Bedossa, Pierre, Adams, Leon A., Zheng, Ming-Hua, Fouad, Yasser, Chan, Wah-Kheong, Mendez-Sanchez, Nahum, Ahn, Sang Hoon, Castera, Laurent, Bugianesi, Elisabetta, Ratziu, Vlad, George, Jacob

“…The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic…”
Get full text

Global burden of liver disease: 2023 update by Devarbhavi, Harshad, Asrani, Sumeet K., Arab, Juan Pablo, Nartey, Yvonne Ayerki, Pose, Elisa, Kamath, Patrick S.

“…Liver disease accounts for two million deaths annually and is responsible for 4% of all deaths (1 out of every 25 deaths worldwide); approximately two-thirds…”
Get full text

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update by Berzigotti, Annalisa, Tsochatzis, Emmanouil, Boursier, Jerome, Castera, Laurent, Cazzagon, Nora, Friedrich-Rust, Mireen, Petta, Salvatore, Thiele, Maja

“…Non-invasive tests are increasingly being used to improve the diagnosis and prognostication of chronic liver diseases across aetiologies. Herein, we provide…”
Get full text

The gut-liver axis in liver disease: Pathophysiological basis for therapy by Albillos, Agustín, de Gottardi, Andrea, Rescigno, María

“…The gut-liver axis refers to the bidirectional relationship between the gut and its microbiota, and the liver, resulting from the integration of signals…”
Get full text

EASL recommendations on treatment of hepatitis C: Final update of the series by Pawlotsky, Jean-Michel, Negro, Francesco, Aghemo, Alessio, Berenguer, Marina, Dalgard, Olav, Dusheiko, Geoffrey, Marra, Fiona, Puoti, Massimo, Wedemeyer, Heiner

“…Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical…”
Get full text

The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis by Younossi, Zobair M., Golabi, Pegah, de Avila, Leyla, Paik, James Minhui, Srishord, Manirath, Fukui, Natsu, Qiu, Ying, Burns, Leah, Afendy, Arian, Nader, Fatema

“…[Display omitted] •Prevalence of NAFLD in patients with type 2 diabetes mellitus is more than 2-fold higher than in the general population.•The overall…”
Get full text

COVID-19: Abnormal liver function tests by Cai, Qingxian, Huang, Deliang, Yu, Hong, Zhu, Zhibin, Xia, Zhang, Su, Yinan, Li, Zhiwei, Zhou, Guangde, Gou, Jizhou, Qu, Jiuxin, Sun, Yan, Liu, Yingxia, He, Qing, Chen, Jun, Liu, Lei, Xu, Lin

“…Recent data on the coronavirus disease 2019 (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to shine…”
Get full text

Burden of liver diseases in the world by Asrani, Sumeet K., Devarbhavi, Harshad, Eaton, John, Kamath, Patrick S.

“…Liver disease accounts for approximately 2 million deaths per year worldwide, 1 million due to complications of cirrhosis and 1million due to viral hepatitis…”
Get full text

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma by Galle, Peter R., Forner, Alejandro, Llovet, Josep M., Mazzaferro, Vincenzo, Piscaglia, Fabio, Raoul, Jean-Luc, Schirmacher, Peter, Vilgrain, Valérie

“…Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90%…”
Get full text

Non-alcoholic fatty liver disease – A global public health perspective by Younossi, Zobair M.

“…As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing…”
Get full text

Epidemiology and surveillance for hepatocellular carcinoma: New trends by Singal, Amit G., Lampertico, Pietro, Nahon, Pierre

“…The burden of hepatocellular carcinoma (HCC) is highest in East Asia and Africa, although its incidence and mortality are rapidly rising in the United States…”
Get full text

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030 by Estes, Chris, Anstee, Quentin M., Arias-Loste, Maria Teresa, Bantel, Heike, Bellentani, Stefano, Caballeria, Joan, Colombo, Massimo, Craxi, Antonio, Crespo, Javier, Day, Christopher P., Eguchi, Yuichiro, Geier, Andreas, Kondili, Loreta A., Kroy, Daniela C., Lazarus, Jeffrey V., Loomba, Rohit, Manns, Michael P., Marchesini, Giulio, Nakajima, Atsushi, Negro, Francesco, Petta, Salvatore, Ratziu, Vlad, Romero-Gomez, Manuel, Sanyal, Arun, Schattenberg, Jörn M., Tacke, Frank, Tanaka, Junko, Trautwein, Christian, Wei, Lai, Zeuzem, Stefan, Razavi, Homie

“…[Display omitted] •Fatty liver disease is a growing cause of cirrhosis and liver cancer globally.•Disease burden is expected to increase with the epidemics of…”
Get full text

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis by Angeli, Paolo, Bernardi, Mauro, Villanueva, Càndid, Francoz, Claire, Mookerjee, Rajeshwar P., Trebicka, Jonel, Krag, Aleksander, Laleman, Wim, Gines, Pere

“…The natural history of cirrhosis is characterised by an asymptomatic compensated phase followed by a decompensated phase, marked by the development of overt…”
Get full text

EASL Recommendations on Treatment of Hepatitis C 2018 by Pawlotsky, Jean-Michel, Negro, Francesco, Aghemo, Alessio, Berenguer, Marina, Dalgard, Olav, Dusheiko, Geoffrey, Marra, Fiona, Puoti, Massimo, Wedemeyer, Heiner

“…Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical…”
Get full text

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19 by Wang, Yijin, Liu, Shuhong, Liu, Hongyang, Li, Wei, Lin, Fang, Jiang, Lina, Li, Xi, Xu, Pengfei, Zhang, Lixin, Zhao, Lihua, Cao, Yun, Kang, Jiarui, Yang, Jianfa, Li, Ling, Liu, Xiaoyan, Li, Yan, Nie, Ruifang, Mu, Jinsong, Lu, Fengmin, Zhao, Shousong, Lu, Jiangyang, Zhao, Jingmin

“…Liver enzyme abnormalities are common in patients with coronavirus disease 2019 (COVID-19). Whether or not severe acute respiratory syndrome coronavirus 2…”
Get full text

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection by Lampertico, Pietro, Agarwal, Kosh, Berg, Thomas, Buti, Maria, Janssen, Harry L.A., Papatheodoridis, George, Zoulim, Fabien, Tacke, Frank

“…Abstract Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination…”
Get full text